Tofacitinib for the management of Ulcerative Colitis

Resumen

Tofacitinib is a small molecule that inhibits the Janus-associated the kinase is a non-biological medication that lacks immunogenicity and can be administered orally. The OCTAVE trials have proven effective in inducing clinical response, clinical remission, and mucosal healing in moderate-to-severe ulcerative colitis (UC). When using tofacitinib in clinical practice, physicians need to know its benefits and risks to stratify patients and use the medication in the safest possible way. The main objectives of this article are to provide a practical guideline for the use of tofacitinib in UC and to identify potential risk factors and complications to avoid them.